Creso Pharma brings pharmaceutical expertise and methodological rigour to the world of medical cannabis and strives for the highest quality in its products, leveraging science and research in order to develop, register and commercialise innovative therapeutic approaches targeting the endocannabinoid system.
Creso Pharma is a leader in cannabidiol (CBD) innovation, developing cannabis- and hemp‐derived therapeutic‐grade Nutraceuticals and Medical Cannabis products with a broad range of applications in both human and animal health. Creso Pharma’s innovative CBD fully plant-based nutraceutical products are non-psychoactive, as they contain only trace amounts of THC.
Focusing on unique and innovative product delivery systems, Creso Pharma is developing therapeutic products and nutraceuticals manufactured according to the highest GMP standards, and maintaining the highest levels of compliance across the supply chain.
Creso Pharma holds worldwide rights for a number of proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. Furthermore, Creso Pharma’s standardised dosage forms are specifically designed and adapted for human health and for animal health, and for several medical conditions including pain and anxiety disorders, metabolic disorders and inflammatory disorders.